Page 4 - Nasdaq Repl News Today

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) CFO Jean M. Franchi sold 11,351 shares of the firm’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $18.05, for a total value of $204,885.55. Following the completion of the transaction, the chief financial officer now owns 128,748 shares […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) CEO Philip Astley-Sparke sold 17,902 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $18.05, for a total transaction of $323,131.10. Following the completion of the transaction, the chief executive officer now directly owns 1,525,278 shares of […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) insider Sushil Patel sold 15,575 shares of the company’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $18.05, for a total value of $281,128.75. Following the sale, the insider now owns 154,571 shares in the company, valued at approximately […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) insider Sushil Patel sold 15,575 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $18.05, for a total value of $281,128.75. Following the completion of the transaction, the insider now directly owns 154,571 shares of […]

Letko Brosseau & Associates Inc. cut its holdings in Replimune Group, Inc. (NASDAQ:REPL – Get Rating) by 67.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,525 shares of the company’s stock after selling 15,275 shares during the period. […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock […]

Piper Sandler restated their overweight rating on shares of Replimune Group (NASDAQ:REPL – Get Rating) in a research note published on Monday morning, Benzinga reports. The firm currently has a $44.00 target price on the stock. A number of other brokerages have also commented on REPL. HC Wainwright boosted their price objective on Replimune Group […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the […]